Denali Therapeutics (DNLI) Research & Development (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Research & Development data on file, last reported at $103.8 million in Q1 2026.

• On a quarterly basis, Research & Development fell 10.65% year-over-year to $103.8 million in Q1 2026; TTM through Mar 2026 was $406.4 million, a 0.18% change from a year earlier, with the FY2025 full-year figure at $418.8 million, up 5.63% from the prior year.
• Research & Development for Q1 2026 stood at $103.8 million, up from $97.9 million in the prior quarter.
• Over the last five years, Research & Development for DNLI reached as high as $128.8 million in Q1 2023 and fell as low as $86.1 million in Q1 2022.
• Historically, Research & Development has averaged $100.1 million across 5 years, with a median of $98.2 million in 2024.
• Across the five-year window, Research & Development surged 49.62% in 2023 and fell 16.92% in 2024, its largest moves.
• Year by year, Research & Development stood at $92.1 million in 2022, then grew by 17.04% to $107.8 million in 2023, then retreated by 7.44% to $99.8 million in 2024, then declined by 1.89% to $97.9 million in 2025, then advanced by 6.07% to $103.8 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $103.8 million in Q1 2026, $97.9 million in Q4 2025, and $101.9 million in Q3 2025.